E-Z-Em gains distribution rights for Gadolite

Article

Pharmacyclics has signed over the North American marketing anddistribution rights for the oral MRI contrast agent Gadolite toE-Z-Em of Westbury, NY. E-Z-Em is by far the market leader in the sale of barium contrastfor gastrointestinal x-ray procedures.

Pharmacyclics has signed over the North American marketing anddistribution rights for the oral MRI contrast agent Gadolite toE-Z-Em of Westbury, NY.

E-Z-Em is by far the market leader in the sale of barium contrastfor gastrointestinal x-ray procedures. As part of the agreement,the companies will collaborate on additional oral agents basedon Gadolite. Financial terms were not disclosed.

The agent has shown promise for abdominal and pelvic imaging,according to the company. Phase III trials were completed in thefirst quarter of 1995. Pharmacyclics expects to file a new drugapplication with the Food and Drug Administration by year-end.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
New Research Examines Radiation Risks with CT Exposure Prior to Pregnancy
Diagnostic Imaging’s Weekly Scan: August 31 — September 6
New Echocardiography Research Suggests Emerging Marker for Cardiomyopathy Detection in Patients with Duchenne Muscular Dystrophy
© 2025 MJH Life Sciences

All rights reserved.